These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 34118298)

  • 21. Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis.
    Hoy SM
    Am J Clin Dermatol; 2023 Jan; 24(1):143-151. PubMed ID: 36538235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. JAK inhibitors in the treatment of atopic dermatitis.
    Chovatiya R; Paller AS
    J Allergy Clin Immunol; 2021 Oct; 148(4):927-940. PubMed ID: 34437922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study.
    Silverberg JI; Kirsner RS; Margolis DJ; Tharp M; Myers DE; Annis K; Graham D; Zang C; Vlahos BL; Sanders P
    J Am Acad Dermatol; 2024 May; 90(5):945-952. PubMed ID: 38340127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Asivatrep, a TRPV1 antagonist, for the topical treatment of atopic dermatitis: Phase 3, randomized, vehicle-controlled study (CAPTAIN-AD).
    Park CW; Kim BJ; Lee YW; Won C; Park CO; Chung BY; Lee DH; Jung K; Nam HJ; Choi G; Park YH; Kim KH; Park M
    J Allergy Clin Immunol; 2022 Apr; 149(4):1340-1347.e4. PubMed ID: 34606832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis.
    Katoh N; Ohya Y; Murota H; Ikeda M; Hu X; Ikeda K; Liu J; Sasaki T; Chu AD; Teixeira HD; Saeki H
    JAAD Int; 2022 Mar; 6():27-36. PubMed ID: 34988493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and safety of lotion, cream, gel, and ointment emollients for childhood eczema: a pragmatic, randomised, phase 4, superiority trial.
    Ridd MJ; Santer M; MacNeill SJ; Sanderson E; Wells S; Webb D; Banks J; Sutton E; Roberts A; Liddiard L; Wilkins Z; Clayton J; Garfield K; Barrett TJ; Lane JA; Baxter H; Howells L; Taylor J; Hay AD; Williams HC; Thomas KS
    Lancet Child Adolesc Health; 2022 Aug; 6(8):522-532. PubMed ID: 35617974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial.
    Zhao Y; Zhang L; Ding Y; Tao X; Ji C; Dong X; Lu J; Wu L; Wang R; Lu Q; Goh AH; Liu R; Zhang Z; Zhang J
    Am J Clin Dermatol; 2021 Nov; 22(6):877-889. PubMed ID: 34374027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Interim Report of a Phase 3, Long-Term, Open-Label Study to Evaluate Efficacy and Safety of Difamilast Ointment in Japanese Infants with Atopic Dermatitis.
    Saeki H; Ohya Y; Baba N; Imamura T; Yokota D; Tsubouchi H
    Dermatol Ther (Heidelb); 2024 Sep; 14(9):2443-2455. PubMed ID: 39075274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective Randomized Double-Blind Vehicle-Controlled Study of Topical Coconut and Sunflower Seed Oil-Derived Isosorbide Diesters on Atopic Dermatitis.
    Nadora D; Burney W; Chaudhuri RK; Galati A; Min M; Fong S; Lo K; Chambers CJ; Sivamani RK
    Dermatitis; 2024; 35(S1):S62-S69. PubMed ID: 38394048
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy and safety of topical OPA-15406, a new phosphodiesterase 4 inhibitor, in Japanese patients with atopic dermatitis for 8 weeks: A phase 2, randomized, double-blind, placebo-controlled study.
    Saeki H; Kawashima M; Sugaya S; Oshiden K; Tsubouchi H
    J Dermatol; 2019 Aug; 46(8):672-679. PubMed ID: 34263481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment with delgocitinib cream improves itch, pain and other signs and symptoms of chronic hand eczema: Results from the Hand Eczema Symptom Diary in a phase IIb randomized clinical trial.
    Bauer A; Thyssen JP; Buhl T; Nielsen TSS; Larsen LS; Østerskov AB; Agner T
    Contact Dermatitis; 2023 Jul; 89(1):46-53. PubMed ID: 37037780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and safety of tacrolimus ointment combined with dupilumab for patients with atopic dermatitis in real-world clinical practice.
    Matsutani M; Imai Y; Inoue Y; Nakatani-Kusakabe M; Natsuaki M; Yamanishi K; Kanazawa N
    J Dermatol; 2021 Oct; 48(10):1564-1568. PubMed ID: 34155694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study.
    Gooderham M; Kircik L; Zirwas M; Lee M; Kempers S; Draelos Z; Ferris L; Jones T; Saint-Cyr Proulx E; Bissonnette R; Bhatia N; Koppel R; Guenthner S; Eads K; Welgus H; Merritt C; Elias M; Navale L; Higham R; Droege M; Berk D
    J Drugs Dermatol; 2023 Feb; 22(2):139-147. PubMed ID: 36745371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Crisaborole Ointment 2% in Chinese Patients Aged ≥ 2 Years with Mild to Moderate Atopic Dermatitis.
    Ma L; Tao X; Liu S; Cheng H; Fang R; Zhao Y; Cha A; Encinas GA; Zhou Y; Deng Y; Zhang J
    Dermatol Ther (Heidelb); 2024 May; 14(5):1229-1243. PubMed ID: 38748345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A single-center, randomized, controlled study on the efficacy of niacinamide-containing body emollients combined with cleansing gel in the treatment of mild atopic dermatitis.
    Zhu JR; Wang J; Wang SS
    Skin Res Technol; 2023 Sep; 29(9):e13475. PubMed ID: 37753690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy and safety of topical difamilast in the treatment of patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials.
    Lu LC; Chao CM; Chang SP; Lan SH; Lai CC
    Expert Rev Clin Pharmacol; 2022 Dec; 15(12):1471-1478. PubMed ID: 36210241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis.
    Fardos MI; Singh R; Perche PO; Kelly KA; Feldman SR
    Expert Rev Clin Immunol; 2022 Mar; 18(3):221-231. PubMed ID: 34637367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema.
    Thomas KS; Armstrong S; Avery A; Po AL; O'Neill C; Young S; Williams HC
    BMJ; 2002 Mar; 324(7340):768. PubMed ID: 11923161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of topical JAK inhibitors in the treatment of atopic dermatitis in paediatrics and adults: A systematic review.
    Sadeghi S; Mohandesi NA
    Exp Dermatol; 2023 May; 32(5):599-610. PubMed ID: 36691705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis.
    Fowler J; Sugarman J; Sher L; Zang C; Werth JL; Myers DE; Graham D; Marfo AA; Takiya L
    Dermatol Ther (Heidelb); 2023 Apr; 13(4):951-960. PubMed ID: 36811773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.